-Advertisement-
-Advertisement-
Genetic and Congenital

Continued use of burosumab in X-linked hypophosphatemia needed to sustain clinical benefit
To sustain clinical benefit from treatment with burosumab in X-linked hypophosphatemia (LH), long-term, continued use appears to be needed, according to results from a Phase 3 open-label extension trial. In this study, 31 patients from a 96-week phase 3 study continue treatment on a burosumab regimen for a further 48...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 MedJournal 360® is a trademark of International Healthcare Media, LLC. All rights Reserved